Normal bone marrow function over 6 years in a patient with dysplastic hematopoiesis and a complex karyotype

Leukemia Research

Volumn 28, Issue 6, 2004, Pages 651-655

  Valent, Peter ^a   Fonatsch, Christa ^b   Stindl, Reinhard ^b   Schwarzinger, Ilse ^a   Haas, Oskar A ^c   Sperr, Wolfgang R ^a   Geissler, Klaus ^a   Lechner, Klaus ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b UNIVERSITY OF VIENNA   (Austria)

^c ST ANNA CHILDREN S HOSPITAL   (Austria)

Author keywords

Karyotype; Myelodysplastic syndromes; Pseudo Pelger Huet granulocytes

Indexed keywords

HEMOGLOBIN;

ADULT; ARTICLE; BLAST CELL; BLOOD CELL COUNT; BONE MARROW; BONE MARROW EXAMINATION; CASE REPORT; CHROMOSOME 13; CHROMOSOME 20; CHROMOSOME 22; CHROMOSOME 7; CYTOPENIA; ERYTHROID CELL; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; FOLLOW UP; GRANULOCYTE; HEMATOPOIESIS; HUMAN; KARYOTYPE; LEUKOCYTE DIFFERENTIAL COUNT; LEUKOCYTE DISORDER; MYELODYSPLASIA; MYELODYSPLASTIC SYNDROME; NEUTROPHIL; PRIORITY JOURNAL; THROMBOCYTE COUNT;

ADULT; BONE MARROW; CHROMOSOME ABERRATIONS; ERYTHROID CELLS; FEMALE; GRANULOCYTES; HEMATOPOIESIS; HUMANS; KARYOTYPING; MYELODYSPLASTIC SYNDROMES; NEUTROPHILS; PELGER-HUET ANOMALY;

EID: 2142829652     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.leukres.2003.10.023     Document Type: Article

References (40)

1. Koeffler H.P., Golde D.W. Human preleukemia. Ann. Int. Med. 93:1980;347
2. Greenberg P.L. The smouldering myeloid leukemic states: clinical and biologic features. Blood. 61:1983;1035
3. Hamblin T. Clinical features in MDS. Leuk. Res. 16:1992;89
4. Kouides P.A., Bennett J.M. Morphology and classification of the myelodysplastic syndromes and their pathologic variants. Semin. Hematol. 33:1996;95
5. Kuriyama K., Tomonaga M., Matsuo T., Ginnai I., Ichimaru M. Diagnostic significance of detecting pseudo-Pelger-Huet anomalies and micromegakaryocytes in myelodysplastic syndrome. Br. J. Haematol. 63:1986;665
6. Shetty V.T., Mundle S.D., Raza A. Pseudo Pelger-Huet anomaly in myelodysplastic syndrome: hyposegmented apoptotic neutrophil? Blood. 89:2001;1273
7. Rosati S., Anastasi J., Vardiman J. Recurring diagnostic problems in the pathology of the myelodysplastic syndromes. Semin. Hematol. 33:1996;111
8. Bennett J.M., Catovsky D., Daniel M.T., Flandrin G., Galton D.A., Gralnick H.R., et al. Proposals for the classification of the myelodysplastic syndromes. Br. J. Haematol. 51:1982;189
9. Bennett J.M., Catovsky D., Daniel M.T., Flandrin G., Galton D.A., Gralnick H.R., et al. The chronic myeloid leukaemias: guidelines for distinguishing chronic granulocytic, atypical chronic myeloid, and chronic myelomonocytic leukaemia. Proposals by the French-American-British Cooperative Leukaemia Group. Br. J. Haematol. 87:1994;746
10. Brunning RD, Bennett JM, Flandrin G, Matutes E, Head D, Vardiman JW, et al. Myelodysplastic Syndromes. In: Jaffe ES, Harris NL, Stein H, Vardiman JW, editors. World Health Organization classification of tumours. Pathology and genetics. Tumours of haematopoietic and lymphoid tissues, vol. 1. 2001. p. 62-73.
11. Tricot G., Boogaerts M.A., de Wolf-Peeters C., van den Berghe H., Verwilghen R.L. The myelodysplastic syndromes: different evolution patterns based on sequential morphological and cytogenetic investigations. Br. J. Haematol. 59:1985;659
12. Preisler H.D. Evolution of secondary hematologic disorders: preMDS → MDS → sAML. Cancer Treat. Res. 108:2001;185
13. Raza A., Mundle S., Shetty V., Alvi S., Chopra H., Span L., et al. A paradigm shift in myelodysplastic syndromes. Leukemia. 10:1996;1648
14. Rosenfeld C., List A. A hypothesis of myelodysplastic syndromes: implications for new therapies. Leukemia. 14:2000;2
15. Sanz G.F., Sanz M.A., Greenberg P.L. Prognostic factors and scoring systems in myelodysplastic syndromes. Haematologica. 83:1998;358
16. Morel P., Hebbar M., Lai J.L., Duhamel A. Cytogenetic analysis has strong prognostic value in de novo myelodysplastic syndromes and can be incorporated in a new scoring system: a report on 408 cases. Leukemia. 7:1993;1315
17. Sanz G.F., Sanz M.A., Vallespi T., Canizo M. Two regression models and a scoring system for predicting survival and planning treatment in myelodysplastic syndromes. a multivariate analysis of prognostic factors in 370 patients. Blood. 74:1989;395
18. Aul C., Gattermann N., Heyll A., Germing U., Derigs G., Schneider W. Primary myelodysplastic syndromes: analysis of prognostic factors in 235 patients and proposals for an improved scoring system. Leukemia. 6:1992;52
19. Mufti G.J., Stevens J.R., Oseier D.G., Hamblin T.J., Machin D. Myelodysplastic syndromes: a scoring system with prognostic significance. Br. J. Haematol. 59:1985;425
20. Greenberg P., Cox C., LeBeau M.M., Fenaux P., Morel P., Sanz G., et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood. 89:1997;2079
21. Fonatsch C., Gudat H., Lengfelder E., Wandt H., Silling-Engelhardt G., Ludwig W.D., et al. Correlation of cytogenetic findings with clinical features in 18 patients with inv(3)(q21q26) or t(3;3)(q21;q26). Leukemia. 8:1994;1318
22. Toyama K., Ohyashiki K., Yoshida Y., Abe T. Clinical implications of chromosomal abnormalities in 401 patients with MDS. a multicentric study in Japan. Leukemia. 7:1993;499
23. Fenaux P., Morel P., Lai J.L. Cytogenetics of myelodysplastic syndromes. Semin. Hematol. 33:1996;127
24. Johansson B., Mertens F., Mitelman F. Cytogenetic deletion maps of hematologic neoplasms: circumstantial evidence for tumor suppressor loci. Gen. Chromosomes Cancer. 8:1993;205
25. Rodrigues Pereira Velloso E., Michaux L., Ferrant A., Hernandez J.M., Meeus P., Dierlamm J., et al. Deletions of the long arm of chromosome 7 in myeloid disorders: loss of band 7q32 implies the worst prognosis. Br. J. Haematol. 92:1996;574
26. Le Beau M.M., Espinosa R. III, Davis E.M., Eisenbart J.D., Larson R.A., Green E.D. Cytogenetic and molecular delineation of a region of chromosome 7 commonly deleted in malignant myeloid diseases. Blood. 88:1996;1930
27. Johnson E.J., Scherrer S.W., Osborne L., Tsui L.C., Oscier D., Mould S., et al. Molecular definition of a narrow interval at 7q22.1 associated with myelodysplasia. Blood. 87:1996;3579
28. Fischer K., Fröhling S., Scherer S.W., Brown J.M.A., Scholl C., Stilgenbauer S., et al. Molecular cytogenetic delineation of deletions and translocations involving chromosome band 7q22 in myeloid leukemias. Blood. 89:1997;2036
29. Iguchi T., Sashida G., Kawakubo K., Tauchi T., Kodama A., Fukutake K., et al. De novo appearance of t(7;13)(q10;q33) in the leukemic phase of myelodysplastic syndrome: a case report. Jpn. J. Clin. Oncol. 32:2002;35
30. Buijs A., van Rompaey L., Molijn A.C., Davis J.N., Vertegaal A.C., Potter M.D., et al. The MN1-TEL fusion protein encoded by the translocation t(12;22)(p13;q11) in myeloid leukemia, is a transcription factor with transforming activity. Mol. Cell. Biol. 20:2000;9281
31. Swansbury G.J., Lawler S.D., Alimena G., Arthur D., Berger R., Van Den Berghe H., et al. Long-term survival in acute myelogenous leukemia: a second follow-up of the Fourth International Workshop on Chromosomes in Leukemia. Cancer Genet. Cytogenet. 73:1994;1
32. Wimazal F., Sperr W.R., Kundi M., Meidlinger P., Fonatsch C., Jordan J.H., et al. Prognostic value of lactate dehydrogenase activity in myelodysplastic syndromes. Leuk. Res. 25:2001;287
33. Sperr W.R., Wimazal F., Kundi M., Fonatsch C., Thalhammer-Scherrer R., Schernthaner G.H., et al. Survival analysis and AML development in patients with de novo myelodysplastic syndromes: comparison of six different prognostic scoring systems. Ann. Hematol. 80:2001;272
34. Pisani F.D., Rainaldi A. Management of high-risk myelodysplastic syndromes. Crit. Rev. Oncol./Hematol. 40:2001;215
35. Anderson J.E. Bone marrow transplantation for myelodysplasia. Blood Rev. 14:2000;63
36. de Witte T., Hermans J., Vossen J., Bacigalupo A., Meloni G., Jacobsen N., et al. Haematopoietic stem cell transplantation for patients with myelodysplastic syndromes and secondary leukemias: a report on behalfe of the Chronic Leukaemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT). Br. J. Haematol. 110:2000;620
37. Runde V., de Witte T., Arnold R., Gratwohl A., Hermans J., van Biezen A., et al. Bone marrow transplantation from HLA-identical siblings as first-line treatment in patients with myelodysplastic syndromes: early transplantation is associated with improved outcome. Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation. Bone Marrow Transp. 21:1998;255
38. Anderson J.E., Appelbaum F.R., Schoch G., Gooley T., Anasetti C., Bensinger W.I., et al. Allogeneic marrow transplantation for refractory anemia: a comparison of two preparative regimens and analysis of prognostic factors. Blood. 87:1996;51
39. Cazzola M., Anderson J.E., Ganser A., Hellstrom-Lindberg E. A patient-oriented approach to treatment of myelodysplastic syndromes. Haematologica. 83:1998;910
40. Bowen D., Culligan D., Jowitt S., Kelsey S., Mufti G., Oscier D., et al. Guidelines for the diagnosis and therapy of adult myelodysplastic syndromes. Br. J. Haematol. 120:2003;187